- Onyx Pharma $ONXX CEO Coles was on the CNBC show "Fast Money" last night 6/6/11 to discuss carfilzomib ASCO data
- Carfilzomib utilizes Captisol formulation technology licensed from Cydex (acquired by Ligand $LGND - click here for research page - sorry that this page is still under construction). LGND stands to receive milestones for NDA submission, FDA approval, royalties, and revenue from captisol raw material sales to ONXX.
- Here are my notes:
- Complete rolling NDA filing in July-August timeframe
- Already have US salesforce in place and hiring additional staff for patient and physician education
- Carfilzomib provides and extra 2-2.5 year survival in multiple myeloma vs current treatments- more than doubles survival
- Won't speculate on potential sales of the drug in multiple myeloma indication
RSS Feed
